INDV (Indivior Pharmaceuticals) Tariff Resilience Score: 7/10 (As of Jun. 30, 2026)


INDV Indivior Pharmaceuticals Inc INDV
69 GF Score
Price $41.26
GF Value $22.98
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Tariff Resilience Score?

Indivior Pharmaceuticals INDV -1.34% 69 Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus rates INDV with a GF Score™ of 69/100 and a GF Value™ of $22.98 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Indivior Pharmaceuticals ranks better than 97.08% on this metric.

Indivior Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Indivior Pharmaceuticals has Indivior PLC, a pharmaceutical company, has moderate tariff exposure due to its global supply chain. However, its strong market position and pricing power provide resilience. Historical tariff impacts have been manageable, and the company can shift suppliers if needed.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Indivior Pharmaceuticals might have Highly Resilient.

Indivior Pharmaceuticals  (NAS:INDV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Indivior Pharmaceuticals Tariff Resilience Score Related Terms

INDV vs KNSA, AMRX, RGC: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indivior Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Indivior Pharmaceuticals's Tariff Resilience Score falls into.


INDV
69GF Score
Indivior Pharmaceuticals Inc INDV
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Indivior Pharmaceuticals (INDV) has a Tariff Resilience Score of 7 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Indivior Pharmaceuticals ranks #30 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Indivior Pharmaceuticals' Tariff Resilience Score too high?
Indivior Pharmaceuticals' current Tariff Resilience Score is 7. Based on the distribution chart, Indivior Pharmaceuticals ranks #30 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Indivior Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Tariff Resilience Score compare to KNSA and AMRX?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #30 out of 1028 companies for Tariff Resilience Score. This places Indivior Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Indivior Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.98, compared to a current price of $41.26 — trading 79.5% above its estimated fair value. The current Tariff Resilience Score is 7. Indivior Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $41.26 is trading 79.5% above its estimated GF Value™ of $22.98. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Tariff Resilience Score: 7
  • GF Value™: $22.98 vs. price of $41.26 (79.5% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
69GF Score

Get the complete analysis for INDV

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.26
Price
$22.98
GF Value